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Abstract
Background: Rotavirus is a worldwide cause of infectious infantile diarrhea that claims over
600,000 lives annually. Recently, two new vaccine candidates have been developed but their efficacy
in developing countries, still remains to be proven. Oral delivery of specific immunoglobulins
provides passive immunity and is a fast acting treatment for rotavirus diarrhea. Probiotic bacteria
have also gained considerable attention lately as treatment for rotavirus diarrhea. Here we report
an evaluation of the therapeutic potential of different probiotics and their combination with anti –
rotavirus antibodies in a mouse model of rotavirus diarrhea.
Results: Of the six probiotic bacteria tested, Lactobacillus rhamnosus strain GG had the strongest
influence in reducing prevalence, duration and severity of diarrhea and was therefore chosen for
combination treatment with immunoglobulins. The combination treatment reduced the diarrhea
outcome measures significantly, prevented histopathological changes and reduced the virus load in
the intestines.
Conclusion: The advantages associated with immunoglobulins and probiotics based therapy is that
the treatment provides a rapid therapeutic effect and is cost efficient. These components do not
require special storage conditions and could potentially complement the rehydration therapy that
is currently used.
Background
Diarrheal diseases remains a major global threat to child
survival [1], and rotavirus is the predominant agent of
severe, dehydrating gastroenteritis in infants and young
children in both developing and industrialized countries
[2,3]. In the Western world, it accounts for a major eco-
nomical loss with a yearly cost of over $ 1 billion in the
management of rotavirus infection in the US alone [4].
The recent development of two new rotavirus vaccines
offers hope but even if an effective vaccine becomes avail-
able, its use may be limited by financial constraints in
developing countries. Moreover, its efficacy in children
with malnutrition and associated immunodeficiency is
questionable. In the absence of an ideal and affordable
specific treatment, Oral Rehydration Therapy (ORT) has
served as a useful treatment that may be rapidly distrib-
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uted, does not require specific storage conditions and is
inexpensive. However, even after achieving a substantial
reduction in mortality from dehydration, ORT has little or
no effect on the course of diarrhea or its associated nutri-
tional morbidity.
The role of secretory IgA, in serving as the first line of
defense against many mucosal pathogens is well estab-
lished. In the case of rotavirus, protection from disease
appears to rely mainly on the production of neutralizing
antibodies against the outer capsid proteins VP4 and
VP7[5]. As a corollary to this, oral delivery of specific anti-
bodies protects against severe rotavirus diarrhea both in
laboratory and clinical settings [6]. We have previously
demonstrated that purified antibodies from hyperim-
mune bovine colostrum and egg yolk from appropriately
immunized hens are effective in the treatment of diarrhea
in rotavirus-infected children [7,8]. However, mass
prophylaxis with HBC has logistic and economic limita-
tions, particularly in developing countries.
In the last few decades, the use of probiotic bacteria has
gained considerable attention as a safe and accessible
form of treatment for gastrointestinal diseases [9,10]. Bac-
teria that have been employed for intervention of diarrhea
of viral or bacterial origin belong to the Lactobacillus or the
Bifidobacterium genus [11]. The therapeutic capacity of cer-
tain probiotic bacteria against rotavirus gastroenteritis has
been suggested to be due to their ability to stabilize and
reinforce the mucosal barrier [12], production of antimi-
crobial substances [13] and stimulation of the local anti-
gen specific and nonspecific immune responses [14,12].
Significant differences have also been noted with regard to
the efficaciousness and mode of action of different strains.
The purpose of our study was to evaluate a combination
therapy with immunoglobulins and probiotics as a
prophylaxis against rotavirus infection in a mouse model.
Results
Reactivity of HBC preparation with RRV
HBC (Hyperimmune Bovine Colostrum) antibodies were
highly reactive against RRV (Rhesus rotavirus) in ELISA,
even at low concentrations (15 ng of total protein, corre-
sponding to 5.4 ng of total immunoglobulins). A control
colostrum preparation Imulin®, did not show any reactiv-
ity against RRV (Figure 1).
In-vitro neutralization test
Since the preparation of the anti-rotavirus HBC used has
had a shelf life of nearly 20 years, it was important to eval-
uate its neutralization capacity against RRV, our challenge
pathogen. MA104 cells grown to confluency were thus
challenged with a fixed amount of RRV (200 FFU) after
the virus had been preincubated anti-rotavirus HBC. Even
a low amount (7 ng total protein of anti-rotavirus HBC
corresponding to 2.5 ng total immunoglobulins) afforded
100% protection of the challenged cells (data not shown).
Evaluation of immunoglobulin and probiotic combinations 
on rotavirus diarrhea
The anti-rotavirus HBC preparation was highly effective in
preventing diarrhea in pups challenged with rotavirus.
Daily administration of 100 µg/dose of anti-rotavirus
HBC (36 µg/dose of immunoglobulins) resulted in a 75%
decrease in diarrhea prevalence on day 2 and 84% on day
3 compared to the percentage prevalence in infected but
untreated mice (p = 0.0047 for day 2 and 0.0007 for day
3). Diarrhea duration and severity was also reduced signif-
icantly from a score of 1.85 and 3.0 in infected and
untreated group to 0.42 for both parameters in mice
receiving 100 µg anti-rotavirus HBC (p < 0.001 for both).
A dose of 10 µg HBC (Table 2) or lower (1 µg or 100 ng
HBC) (data not shown), did not impart any protection
against rotavirus challenge.
For subsequent development of combination treatments,
we started by optimizing the dose of probiotic bacteria
being fed, using Lactobacillus paracasei as a reference [15].
The strain was previously considered a Lactobacillus casei
ATCC 393T variant cured of plasmid pLZ15 and has been
referred in the past as L. casei or Lactobacillus zeae ATCC
393 (pLZ15-). Recently, using molecular techniques, it has
correctly been identified as L. paracasei. For simplicity, we
will refer to this strain as L. paracasei [15] in this article.
This strain is 'molecularly accessible' and has previously
been used for heterologous protein expression [16].
Reactivity of Hyperimmune bovine colostrums (HBC) against  RRV Figure 1
Reactivity of Hyperimmune bovine colostrums 
(HBC) against RRV. HBC preparation is highly reactive 
against RRV as assessed by ELISA. ELISA plates were coated 
with RRV and HBC was added in different dilutions. The 
reaction was developed using anti-bovine AP conjugated sec-
ondary antibody. Control colostrums preparation (Imulin®) 
does not show any cross-reactivity with RRV even at high 
concentrations.BMC Microbiology 2007, 7:86 http://www.biomedcentral.com/1471-2180/7/86
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Mouse pups were fed three different doses of L. paracasei
[15] (1010, 108 or 106 CFU/dose) and challenged with
RRV. The daily administration of the bacteria at 108 CFU
resulted in a small, statistically non-significant reduction
in diarrhea prevalence. However, the dose of 1010 CFU
was not significantly better than 108 CFU and we thus
decided on using the lower dose, 108 CFU as the standard
dose for subsequent experiments (Figure 2).
In total, bacterial strains from 6 different Lactobacillus spe-
cies were evaluated for their prophylactic action against
RRV-induced diarrhea in our mouse model. The cumula-
tive results of the outcome measures are summarized in
Table 1. L. paracasei [15] induced a modest (non-signifi-
cant) reduction in diarrhea prevalence to 65% and no sig-
nificant improvement in diarrhea duration or severity was
observed.  Lactobacillus rhamnosus strain GG showed a
strong anti-rotavirus capacity and reduced the diarrhea
prevalence to 41% compared to 93% in infected but
untreated mice (p < 0.001) (Table 1). The diarrhea dura-
tion and severity was also significantly reduced (p
<0.001). The 'anti-rotavirus' activity of the bacteria is
dependant on viability or is destroyed during heat inacti-
vation, as heat inactivated L. rhamnosus GG did not impart
protection in mice (Table 1). Lactobacillus reuteri strain
SD2112 conferred a small but non-significant reduction
in diarrhea prevalence, duration and severity (Table 1).
It was previously noted that anti-rotavirus HBC at 10 µg/
dose could not protect against development of severe
rotavirus diarrhea. We therefore used HBC at this dose to
screen for additive or synergistic combinations with pro-
biotic bacteria. L. paracasei [15], L. reuteri SD2112 and
Lactobacillus paracasei strain NCC 2461 (referred to as
ST11 in (23)) were selected along with L. rhamnosus GG to
develop the combination treatment. Complementation of
L. paracasei [15] or L. rhamnosus GG with HBC was more
protective than either bacteria given alone. Combination
of L. paracasei [15] and HBC reduced the diarrhea preva-
lence to 33% on day 2 and 3 whereas it remained high
(70–80%) in L. paracasei [15] only treated mice (relative
reduction of 58% on day 2 and 53% on day 3). The
diarrhea duration was also significantly reduced in the
combination group (p <0.05) (Figure 3A). As observed
previously, L. rhamnosus GG could itself induce a statisti-
cally significant reduction in diarrhea prevalence in chal-
lenged mice on day 3 (p = 0.009) and mollified disease
severity (p < 0.05). Nonetheless, the combination of bac-
teria with 10 µg anti-rotavirus HBC caused a further 26%
relative reduction in diarrhea prevalence on day 3 and sig-
nificantly reduced the duration and severity of the disease
(p < 0.05) (Figure 3B). Combination of L. reuteri SD 2112
and HBC did not show the same efficacy in reducing
Optimization of the dose for oral treatment with probiotic  bacteria using L. paracasei [15] as a reference strain Figure 2
Optimization of the dose for oral treatment with 
probiotic bacteria using L. paracasei [15] as a refer-
ence strain. L. paracasei [15] was fed in different doses and 
the pups challenged with RRV on day 0. 108 CFU of bacteria 
was selected as the optimal dose for subsequent treatment 
with probiotic bacteria.
Table 1: Outcome measures of diarrhea among mice receiving different probiotic bacteria and challenged with RRV
Strains/Treatment a Number of animals Highest Prevalence (%) Duration (mean ± SE) Severity (mean ± SE) 
L. paracasei b 17 65 1.94 ± 0.20 2.88 ± 0.35
L. reuteri SD2112 (ATCC 55730) 10 70 1.40 ± 0.30 2.00 ± 0.47
L. rhamnosus GG (ATCC 53103) 20 41*** 0.65 ± 0.15*** 0.85 ± 0.19***
Heat killed L. rhamnosus GG (ATCC 
53103)
8 75 1.63 ± 0.32 2.37 ± 0.53
L. paracasei NCC 2461 (ST11) 10 90 1.60 ± 0.26 2.50 ± 0.40
L. johnsonii NCC 533 (La-1) 8 88 1.87 ± 0.12 2.75 ± 0.25
S. thermophilus NCC 2496 10 100 1.50 ± 0.16 2.70 ± 0.39
Infected and untreated 27 93 1.81 ± 0.17 2.96 ± 0.32
a All bacteria were daily administered at a concentration of 108 CFU/dose
b previously thought to be L. casei ATCC 393 [15]
* p < 0.05 vs Untreated
**p < 0.01 vs Untreated
*** p < 0.001 vs UntreatedBMC Microbiology 2007, 7:86 http://www.biomedcentral.com/1471-2180/7/86
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diarrhea but achieved a modest improvement over L. reu-
teri SD2112 given alone on both day 2 and 3 (16% and
14% relative reduction, p = 0.035 for day 3) (Figure 3C).
L. paracasei NCC 2461 by itself, or in combination with
HBC, did not protect against RRV-induced diarrhea (Fig-
ure 3D and Table 2).
Histopathological analysis
Formalin fixed intestinal tissue sections from mice treated
with different treatment modalities were blindly analyzed
for histopathological changes associated with rotavirus
infection [17]. The RRV infected, untreated group pre-
sented a typical histology associated with rotavirus infec-
tion with swollen villus tips and vacuolization. The villus
tips were unstainable due to epithelial cell death (Figure
4A). The histo-pathology showed reduced vacuolization
in pups receiving L. rhamnosus GG or 10 µg HBC alone
(Figure 4B and 4C). In comparison, the combined treat-
ment of L. rhamnosus GG with 10 µg of HBC prevented
histological changes completely (Figure 4D) as was also
seen with 100 µg of HBC (Figure 4E). The negative control
mice that were not infected showed a normal histology
(Figure 4F).
Real Time PCR
Since L. rhamnosus strain GG based therapy (either only
bacteria or combined with HBC) significantly reduced
diarrhea prevalence among the challenged mice and also
reduced the associated histopathological changes, we
wanted to confirm whether this therapy also had an effect
on the virus load. Total cellular RNA isolated from intesti-
nal tissue sections of pups treated with L. rhamnosus strain
GG based treatment modalities (bacteria alone or com-
bined with 10 µg HBC) were therefore analyzed by real
time PCR for number of copies of the RRV vp7 gene. The
virus load in infected, untreated mice was higher than in
all the treatment groups (geometric mean 2038). As
expected, no virus could be detected in uninfected nega-
tive control mice. Treatment with 100 µg of HBC was able
to reduce the virus load in challenged mice well below the
detection level of 10 vp7 copies and hence, corroborated
the normal histology (geometric mean 2) (p < 0.0001). In
comparison, the lower dose of 10 µg could not achieve a
similar clearance of virus and the load was still high with
a geometric mean of 102. Treatment with L. rhamnosus GG
alone was also able to reduce the virus load significantly
(geometric mean 53) (p = 0.001). The combined treat-
ment of 10 µg of HBC and L. rhamnosus GG resulted in a
statistically significant reduction of virus load in compar-
ison to infected and untreated mice (geometric mean 15)
(p = 0.0005) (Figure 5).
Discussion
One of the advantages of using immunoglobulin-based
treatments against rotavirus-induced diarrhea is the
immediacy of action, which the conventional active
immunization regimens lack. We have previously
reported that severe rotavirus diarrhea in children can be
successfully treated using antibodies derived from colos-
trum of immunized cows (HBC antibodies) [7,18,19].
Our preliminary results from this study establishes that
these antibodies have been well preserved even after a
long shelf life (18 years) and are fully functional in
imparting protection against rotavirus infection in vitro
and  in vivo. However, treatment for rotavirus diarrhea
purely based on HBC, however effective, is not practical
and may be offset by the costs involved for mass prophy-
laxis. It is thus imperative to find alternative methods to
make immunoglobulin based therapy economically via-
ble.
Table 2: Duration and severity of diarrhea in different treatment groups with or without complementation with anti-rotavirus HBC
Groups Number of animals Duration (mean ± SE)* Severity (mean ± SE)
Untreated 27 1.85 ± 0.17 3.00 ± 0.33
100 µg HBC 12 0.42 ± 0.23*** 0.42 ± 0.23 ***
10 µg HBC 8 1.62 ± 0.32 2.62 ± 0.53
L. paracaseib 10 1.60 ± 0.27 a
L. paracaseib + 10 µg HBC 9 0.78 ± 0.28 * a
L. reuteri SD 2112 10 1.20 ± 0.20 2.00 ± 0.47
L. reuteri SD 2112 + 10 µg HBC 10 1.20 ± 0.20 2.00 ± 0.47
L. paracasei NCC 2461 10 1.80 ± 0.29 2.50 ± 0.40
L. paracasei NCC 2461+ 10 µg HBC 7 2.14 ± 0.26 3.43 ± 0.53
L. rhamnosus GG 10 0.90 ± 0.23 1.20 ± 0.32*
L. rhamnosus GG + 10 µg HBC 8 0.62 ± 0.32* 0.87 ± 0.48 *
*** p < 0.001, * p < 0.05 Vs. Untreated
a absolute values for severity are not available, but they are at least as much as the duration.
b previously thought to be L. casei ATCC 393 [15]BMC Microbiology 2007, 7:86 http://www.biomedcentral.com/1471-2180/7/86
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Probiotic bacteria offer a cheaper platform for the man-
agement of rotavirus diarrhea. Among the various mecha-
nisms suggested for the action of probiotics is the ability
to survive gut transit and in the process cause stabilization
of the mucosal barrier, production of anti-microbial com-
pounds and stimulation of the mucosal immune response
leading to an increase in secretory IgA [14]. It is, however,
difficult to determine whether the health promoting
effects of the probiotic bacteria are due to a specific inhi-
bition of the pathogen in question or a reflection of a
more complex interaction between host, pathogen and
the probiotic.
We tested six different lactobacilli for protection against
rotavirus-induced diarrhea. Mouse pups received two pro-
phylactic doses of bacteria before challenge with rotavi-
rus, followed by daily therapeutic administration of
respective bacteria and monitoring for diarrhea symp-
toms. We noted a strong anti-rotavirus activity of L. rham-
nosus strain GG, corroborating results obtained previously
by other researchers in clinical trials [20,21]. However, the
same bacterium, when heat killed, was unable to impart
protection against rotavirus challenge, suggesting that the
inhibitory effect against rotavirus is either dependent on
viability or is a heat labile factor. Interestingly a clinical
evaluation of treatment with live or heat inactivated L.
rhamnosus GG against rotavirus diarrhea found that the
inactivated bacteria did not effectively stimulate local IgA
production, thus increasing the chances of reinfection
[14]. L. reuteri SD2112, which has previously shown a
Anti-rotavirus HBC combination treatment with different species of Lactobacilli Figure 3
Anti-rotavirus HBC combination treatment with different species of Lactobacilli. Mice were fed lactobacilli daily, 
either alone or supplemented with 10 µg anti-rotavirus HBC and challenged with RRV on day 0. Diarrhea prevalence was 
recorded every day and is presented as percentage prevalence. Test of significance was performed using Fischer's exact test. 
(A) L. paracasei [15], in combination with HBC, was able to achieve a 58% better protection than that imparted by bacteria 
alone on day 2. On day 3 the combination treatment achieved statistically significant reduction in diarrhea prevalence in com-
parison to infected but untreated mice (p = 0.001) and 53% better protection than L. paracasei [15] alone. (B) L. rhamnosus GG 
alone caused a significant reduction in diarrhea prevalence in comparison to untreated mice on day 3 (p = 0.009) and in combi-
nation with HBC this effect was further enhanced (p = 0.003). (C) On day 3, protection conferred by combined therapy of L. 
reuteri strain SD2112 with 10 HBC µg was statistically significant in comparison to untreated mice (p = 0.035). (D) Administra-
tion of either L. paracasei strain NCC 2461 alone or supplemented with anti-rotavirus HBC did not change the diarrhea profile 
which resembled that of the untreated mice.BMC Microbiology 2007, 7:86 http://www.biomedcentral.com/1471-2180/7/86
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positive effect in the treatment of rotavirus-related
diarrhea in clinical trials [22], was only marginally protec-
tive in our mouse model and L. paracasei NCC 2461,
which was recently shown to have no significant effect in
resolving rotavirus-induced gastroenteritis [23], was not
protective at all in our animal model. Thus, it appears that
the basic mechanism of probiotics, at least in relation to
rotavirus infection, may be paralleled in the mouse gastro-
intestinal tract as in the humans and the mouse model
may thus potentially serve as a premonitory assessment of
the therapeutic effect of candidate probiotics against rota-
virus.
In order to introduce specificity to the basic probiotic
therapy, we complemented bacteria with a low dose of
polyclonal anti – rotavirus antibodies. Four lactobacilli
with wide ranging anti-rotavirus properties were adminis-
tered in combination with antibodies. Combination treat-
ment of L. rhamnosus GG and antibodies was the most
potent among all the combinations. Not only did this
combination reduce the outcome measures of diarrhea,
which was also partially achieved by feeding of L. rhamno-
sus  GG alone, but also alleviated histopathology and
reduced the virus load in the small intestine. The role of
secretory IgA and passively administered antibodies as the
primary protection against many invading mucosal path-
ogen including rotavirus is an established tenet. In fact,
the probiotic activity of L. rhamnosus GG with respect to
rotavirus infection has been linked to an increased rate of
production of IgA in the mucosa [14]. We also attempted
to study the possible contribution of L. rhamnosus GG in
stimulating IgA responses in the gastrointestinal mucosa
of the pups through ELISA. However, such an analysis is
technically difficult, due to the high background by mater-
nally derived IgA through milk. We hypothesize that by
administering antibodies and L. rhamnosus GG together,
we have achieved a combination where the infection is
effectively controlled by the two components. The small
amount of administered antibodies blunts the initial
infection, but is clearly not enough to abrogate it. The co-
administered L. rhamnosus GG may potentially boost this
protection owing to its ability to muster a local IgA
response.
To this end, it is reasonable to assume that the cornerstone
in achieving protection against rotavirus infection could
be to optimize delivery of functional antibodies to the
intestinal mucosa. Genetically engineering lactobacilli for
in-situ  expression of antibody fragments could achieve
this objective [16,24]. Multiple antibody specificities can
be expressed by the lactobacilli that can mimic a polyva-
lent antibody preparation. The expression of various anti-
body fragments on lactobacillus surface would increase
the avidity for binding several fold. Additionally, the pro-
biotic activity associated with the carrier lactobacilli
would be an added advantage. We are thus currently
developing lactobacilli that express anti-rotavirus anti-
body fragments on the bacterial surface.
Problems such as high production costs, special storage
conditions, difficulties in distribution to the affected pop-
ulation and the need of technical expertise for vaccine
delivery constitute potential drawbacks of active immuni-
zation. Furthermore, efficacy of the newly licensed vac-
cines in the affected population and the recommended
use only in children younger than 3 months are issues that
need to be addressed. As a principle, inducing a protective
response by vaccination would take longer than the time
between exposure to rotavirus and the onset of disease.
Passive immunization with protective antibodies is the
only currently available intervention that provides imme-
diate protection in persons with impaired immunity.
Freeze-dried immunoglobulins and probiotics could also
be used as a prophylactic measure when a seasonal
dependent rotavirus outbreak in suspected. Although the
Hematoxylin/Eosin stained sections of jejunum from mice  treated with different formulations Figure 4
Hematoxylin/Eosin stained sections of jejunum from 
mice treated with different formulations. Tissue sec-
tions were excised and embedded in paraffin. HE staining was 
performed by standard protocols and the samples assessed 
blindly for signs of rotavirus infection. (A) infected and 
untreated mice shows typical signs of grave rotavirus infec-
tion with swollen and vacuolized villus tips. (B) L. rhamnosus 
GG treated mice show moderately resolved histopathology 
similar to (C) 10 µg/dose HBC treated mice. (D) L. rhamno-
sus GG combined with HBC is able to resolve the histopa-
thology to normalcy. (E) no histopathology associated with 
treatment with 100 µg/dose HBC. (F) uninfected control 
mice.BMC Microbiology 2007, 7:86 http://www.biomedcentral.com/1471-2180/7/86
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current treatment was administered as a prophylaxis in
this study, both L. rhamnosus GG and oral immunoglobu-
lin therapy have been previously shown to have therapeu-
tic effect against rotavirus diarrhea in children [20,21,7].
A combination based on these two components may
therefore also have therapeutic efficacy but this hypothe-
sis needs further testing. Freeze-dried immunoglobulins
and probiotics could be used to complement the standard
oral rehydration therapy and may help to relieve the
immense disease burden posed by rotavirus in the devel-
oping world.
Conclusion
A combination of L. rhamnosus GG with specific bovine
colostrum – derived immunoglobulins is an effective pro-
phylactic measure for rotavirus diarrhea in the infant
mouse model. This can be a highly cost efficient way of
managing rotavirus diarrhea and may thus represent the
prophylaxis of choice for selected group of children.
Methods
Anti – rotavirus antibodies
The Hyperimmune Bovine Colostrum (HBC) used was
produced by vaccination of pregnant cows in a Swiss dairy
farm with human strains of rotavirus, i.e. Wa, RV3, RV5
and ST3, representing serotypes 1 to 4. The preparation
and the antiviral activity of the HBC concentrate is
described in detail elsewhere [19]. In brief, the concen-
trate was prepared from colostrums by skimming, pas-
teurization and removal of milk fat, casein, lactose and
mineral salts. The product was then sterile filtered, and the
resulting whey protein solution was freeze-dried. The
immunoglobulin concentration of the powder was 36 g/
100 g of dried anti-rotavirus milk concentrate. The com-
positions of the immunoglobulin were 75% IgG1, 3%
IgG2, 17% IgA and 6% IgM. The neutralization titers as
measured in type neutralization test against the serotype
were as follows: serotype 1, 7500; serotype 2, 2000; sero-
type 3, 4500; and serotype 4, 4500 [19]. The negative con-
trol was prepared from milk from nonimmunized cows
(Imulin®; New Zealand Dairy Board, Wellington, New
Zealand) (22% lactose). Both the HBC and placebo were
stored at room temperature.
Virus cultivation
Rhesus rotavirus (RRV) was cultured in MA104 cells as
previously described. The virus titre was calculated using
immunoperoxidase staining of infected cells [25]. A single
batch of the RRV was used for the study.
Real time PCR of intestinal tissue sections for RRV vp7 gene Figure 5
Real time PCR of intestinal tissue sections for RRV vp7 gene. Tissue samples were excised from small intestines and 
total cellular RNA was extracted. Real time PCR was performed for rotavirus vp7 gene. The bars represent geometric mean of 
the virus load after normalization with housekeeping gapdh gene. The combination of 10 µg HBC and L. rhamnosus GG was 
able to achieve a statistically significant reduction of virus load (as tested by Fischer's test). *** p < 0.0001, ** p = 0.0005, * p = 
0.0016BMC Microbiology 2007, 7:86 http://www.biomedcentral.com/1471-2180/7/86
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Reactivity of HBC against RRV (ELISA)
ELISA 96 well plates were coated with rabbit anti-human
rotavirus anti-serum (1:1000) at 4°C overnight. After two
washes with PBS, diluted RRV was added (1:100) and left
for binding overnight at 4°C. The plates were then
blocked with PBS-BSA (2%) for 2 h and subsequently,
HBC was added in two-fold dilutions prepared in PBS and
the plate was incubated at 37°C for 1 h. After washing,
alkaline phosphatase conjugated anti-bovine IgG was
added (1:1000) (Zymed, San Francisco, USA) and the
plate was incubated for another 1 h at 37°C. The reaction
was developed with p-nitrophenyl phosphate in diaeth-
anolamine buffer and the plate was read at 405 nm.
Neutralization assay
HBC was serially diluted four-fold in Dulbecco's PBS and
incubated for 1 h at room temperature with 200 foci form-
ing units (FFU) of trypsin-activated RRV in a final volume
of 200 µl. Confluent MA104 cell monolayers were then
inoculated with the mixture. The inoculated plates were
incubated at room temperature for 1 h, washed with MEM
medium, supplied with fresh MEM medium supple-
mented with antibiotics (gentamycin, penicillin and
streptomycin) and incubated at 37°C in a 5% CO2 atmos-
phere for 18 h. Monolayers were fixed and stained with
immunoperoxidase as previously described [25]. A reduc-
tion in the number of RRV-infected cells greater than 60%
with respect to the number in control wells was consid-
ered to indicate neutralization [5].
Bacterial strains and growth conditions
Four different Lactic acid bacteria were obtained from
Nestec, Nestlé, Lausanne, L. paracasei strain NCC 2461
(ST11), L. rhamnosus strain GG (ATCC 53103), L. johnsonii
strain NCC 533 (La-1) [26], L. rhamnosus strain NCC 596
and Streptococcus thermophilus strain NCC 2496. The L. reu-
teri  strain ATCC 55730 (SD2112) was obtained from
Biogaia, Sweden. L. paracasei [15] (previously named L.
casei 393 pLZ15-) [15] was obtained from Peter Pouwels
(TNO Institute, the Netherlands). Lactobacilli were recon-
stituted and cultured in MRS broth (Difco, Sparks, MD,
USA) in standing aerobiosis conditions at 37°C. S. ther-
mophilus strain NCC 2496 was cultured in M17 media
with lactose supplementation in standing aerobiosis at
42°C.
Animal Experiments
All animal experiments were approved by the local ethical
committee of the Karolinska Institutet at Karolinska Uni-
versity Hospital in Huddinge. Pregnant BALB/c mice were
purchased from Møllegard, Denmark. Four-day-old pups
were used for the study. Different bacteria or antibody
preparations were administered to pups once daily in a 10
µl volume starting on day -1 and continued until day 3.
Infections were made orally on day 0 using 2 × 107 FFU
RRV in a 10 µl volume. Immunoglobulins and freshly cul-
tured bacteria were resuspended in PBS at the desired con-
centrations. Occurrence of diarrhea was recorded daily
until day 4. Pups were euthanized using intra-peritoneal
pentobarbital on day 4. Sections of small intestines were
stabilized in RNAlater® (Qiagen, Hilden, Germany) for
RNA isolation or fixed in neutral buffered formalin for
histopathological analysis.
Histopathological Analysis
Sections of small intestine were excised and perfused with
formalin. The sections were kept immersed in formalin
for a day after which they were transferred to 70% etha-
nol. The samples were embedded in paraffin and sections
were stained with hematoxylin and eosin using standard
protocols. The sections were analyzed blindly for signs of
rotavirus infection associated pathology [17].
Real time PCR
Total cellular RNA was isolated from small intestinal tis-
sue and used for real-time PCR analysis after digestion of
residual genomic DNA using RNase free DNase® (Qiagen,
Hilden, Germany). EZ RT-PCR®  core reagent kit (PE
Applied Biosystems) was used for real- time PCR quantifi-
cation of rotavirus vp7 RNA as described before [16]. The
RNA samples from each animal were normalized for the
internal housekeeping gene GAPDH [27]. Detection of no
virus or less than 10 virus vp7 RNA copies by PCR was
defined as clearance from infection.
Statistics
Diarrhea in the pups was assessed on the basis of consist-
ency of feces. Watery diarrhea was given a score of 2 and
loose stool was given a score of 1, no stool or normal stool
was given a score of 0. Presence or absence of diarrhea was
compared among treatment groups in a day-wise manner
by Fischer's exact test and was presented as percentage
diarrhea in graphs. Severity was defined as the sum of
diarrhea scores for each pup during the course of the
experiment (severity = Σ diarrhea score (day 1 + day 2 +
day 3 + day 4)) and duration was defined as the total sum
of days with diarrhea. Both severity and duration were
analyzed by Kruskal-Wallis and Dunn tests. Differences in
the intestinal virus load as assessed by real-time PCR were
tested using the Mann-Whitney test.
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